Company Overview and News
I would like to believe that GOV/SIR deal will go through, especially as it is orchestrated by the same RMR Group (parent of both companies), however I do not see how it can be approved by GOV shareholders given the unfair dividend cut.
HSE TPCO NSFC MEG FMBI RMR MEGEF TRNC HUSKF AET TPUB
2018-10-05 malaymail - 1
WASHINGTON, Oct 5 — The US newspaper group known as Tronc announced yesterday it was reverting back to its old name Tribune Publishing, two years after a rebranding effort that drew widespread derision.
TRNC NYTAB TPUB
Tronc, Inc. — the owner of the Chicago Tribune, Baltimore Sun and New York Daily News — is changing its name back to Tribune Publishing Company, just over two years after it underwent one of the most-maligned corporate rebrandings in recent memory.
CHICAGO, Oct. 04, 2018 (GLOBE NEWSWIRE) -- tronc, Inc. (NASDAQ:TRNC) announced today its decision to rename the company Tribune Publishing Company. The change to Tribune Publishing Company will formally take effect on Tuesday, October 9, 2018 at 4:15 pm, Eastern Daylight Time.
FORT LAUDERDALE, Fl., Sept. 26, 2018 (GLOBE NEWSWIRE) -- las personalidades televisivas Bill y Giuliana Rancic aparecerán en el THRIVE del sur de Florida, el principal retiro de bienestar y salud.
FORT LAUDERDALE, Fl., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Television personalities Bill and Giuliana Rancic will appear at this year’s THRIVE South Florida, a premier health and wellness retreat.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET